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Trends in Staphylococcus aureus infections are not 
well described. To calculate incidence in overall S. aureus 
infection and invasive and noninvasive infections according 
to methicillin susceptibility and location, we conducted 
a 10-year population-based retrospective cohort study 
(1999–2008) using patient-level data in the Veterans Affairs 
Maryland Health Care System. We found 3,674 S. aureus 
infections: 2,816 (77%) were noninvasive; 2,256 (61%) 
were methicillin-resistant S. aureus (MRSA); 2,517 (69%) 
were community onset, and 1,157 (31%) were hospital 
onset. Sixty-one percent of noninvasive infections were 
skin and soft tissue infections; 1,112 (65%) of these were 
MRSA. Ten-year averaged incidence per 100,000 veterans 
was 749 (± 132 SD, range 549–954) overall, 178 (± 41 
SD, range 114–259) invasive, and 571 (± 152 SD, range 
364–801) noninvasive S. aureus infections. Incidence of all 
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S. aureus infections signiﬁ   cantly increased (p<0.001), 
driven by noninvasive, MRSA, and community-onset 
infections (p<0.001); incidence of invasive S. aureus 
infection signiﬁ  cantly decreased (p<0.001).
S
taphylococcus aureus exists as a commensal organism 
living on the human body in equilibrium with other 
bacteria and as a common agent associated with a spectrum 
of diseases ranging from mild, noninvasive skin and soft 
tissue infections (SSTIs) to invasive, life-threatening 
bloodstream infections. Increasing incidence of infections 
caused by methicillin-resistant S. aureus (MRSA) has 
complicated treatment of S. aureus infection. Previously 
MRSA infections were problematic primarily among 
hospitalized persons or persons exposed to the health care 
settings. However, since the 1990s, MRSA infections 
have become more prevalent in healthy, younger persons 
who have little to no exposure to health care settings. Of 
particular concern is the rapid increase in MRSA SSTIs 
reportedly driven by emergence of a new MRSA strain, 
USA300 (1,2).
Despite these changes, the epidemiology of S. aureus 
infection, particularly the total effect of infection in the 
United States, is not well described. Several population-
based studies on S. aureus infections exist; however, 
these studies focused on hospital-based populations (3–6), 
MRSA infection (7–9), non-US populations (10–12), or 
only estimated the impact of invasive S. aureus disease 
(10,13–15). Additionally, population-level changes in 
incidence, particularly before and after USA300 MRSA 
emerged, are largely unknown. To describe overall trends 
and recent changes in the incidence of S. aureus infection 
while differentiating between invasive and noninvasive, 
community- and hospital-onset, and methicillin-susceptible 
and -resistant S. aureus infections, we conducted a 
retrospective population-based study. 
Methods
Data Source
Our study used data from the Veterans Affairs 
Maryland Health Care System (VAMHCS) over a 10-year 
period (1999–2008). VAMHCS, a large, integrated health 
care system, comprises 3 medical centers (Baltimore VA 
Medical Center, Perry Point VA Medical Center, and the 
Baltimore VA Rehabilitation and Extended Care Center), 
≈730 inpatient beds, and 5 community-based outpatient 
clinics. VAMHCS uses an electronic health information 
system known as the Veterans Health Information Systems 
and Technology Architecture (VistA). This system is used 
to collect and maintain all health information at each VA 
medical facility, including the VAMHCS. VAMHCS’s 
electronic medical records and administrative data, 
including codes from the International Classiﬁ  cation  of 
Diseases, 9th Revision, Clinical Modiﬁ  cation  (ICD-9-
CM), and microbiology culture results collected from the 
VistA served as the primary data source for this study. 
The VAMHCS Research and Development Committee 
and the University of Maryland, Baltimore Institutional 
Review Board approved this study. Given that data were 
retrospectively obtained from VistA, informed consent 
requirements were waived.
S. aureus Culture Collection and Classiﬁ  cation
We collected data during October 1, 1998–September 
30, 2008, on all S. aureus–positive blood and clinical 
cultures (excluding surveillance and fecal and nasal 
cultures) identiﬁ   ed through microbiologic accession 
number, date, time, and specimen type (e.g., blood, skin). 
Each positive culture was classiﬁ  ed as originating from 
a sterile or a nonsterile body site. We deﬁ  ned a sterile 
body site according to Centers for Disease Control and 
Prevention Active Bacterial Core surveillance criteria, 
and all other body sites were classiﬁ  ed as nonsterile (13). 
We deﬁ  ned a unique culture as the ﬁ  rst S. aureus–positive 
culture obtained from a patient during a 6-month period. 
If cultures were obtained from a sterile and a nonsterile 
site from the patient during the same period, we chose the 
culture from the sterile site.
For     S. aureus–positive cultures obtained during 
an outpatient visit for which the patient was not 
subsequently hospitalized within a 72-hour period after 
culture, we obtained all ICD-9-CM codes associated 
with all of the patient’s outpatient visits on the day of 
culture. For S. aureus–positive cultures obtained during 
an outpatient visit for which the patient was subsequently 
hospitalized within a 72-hour period after culture, we 
collected the outpatient and hospital discharge ICD-9-
CM codes. Finally, we obtained all ICD-9-CM discharge 
codes for S. aureus–positive cultures obtained during a 
hospitalization. Using information from previous studies, 
we developed a comprehensive list of ICD-9-CM codes 
for S. aureus–related infections and categorized them by 
the site of infection most consistent with the associated 
code (16).
We determined an invasive S. aureus infection on 
the basis of S. aureus isolation from a clinical or blood 
culture from a normally sterile body site, such as blood, 
cerebrospinal ﬂ  uid, pleural ﬂ  uid, pericardial ﬂ  uid, peritoneal 
ﬂ  uid,  joint/synovial  ﬂ   uid, bone, internal body site, and 
muscle. Identiﬁ  cation of noninvasive S. aureus infection 
was based on isolation of S. aureus from a clinical culture 
of a nonsterile site, without a concurrent culture from a 
sterile site obtained during the same 6-month period, and 
at least 1 ICD-9-CM code for S. aureus–related infection 
from the outpatient visit or hospitalization associated with 
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the positive culture. For a noninvasive infection, we based 
the requirement of a matching ICD-9-CM code along with 
positive culture on concerns that S. aureus obtained from 
a sample from a nonsterile body site can represent either 
infection or colonization. In a substudy that used a random 
sample of cases, we estimated that an ICD-9-CM code for 
S. aureus–related infection plus positive clinical culture 
(from a nonsterile site) increases the probability of a true 
noninvasive S. aureus infection by ≈23.8% over positive 
clinical culture alone (16).
Positive cultures obtained after the ﬁ  rst 48 hours of 
hospitalization, rehabilitation, or long-term stay were 
classiﬁ  ed as hospital onset and all others as community 
onset. All S. aureus infections were classiﬁ  ed according 
to methicillin susceptibility on the basis of in vitro 
susceptibility to oxacillin. All MRSA infections were 
grouped into the following epidemiologic categories: 
health care–associated community onset, deﬁ  ned as cases 
in persons with at least 1 listed risk factor in the past 12 
months; health care–associated hospital onset, deﬁ  ned as 
cases in persons who have a positive culture within 48 hours 
after hospitalization; or community-associated, deﬁ  ned 
as cases in persons with no documented health care–
associated community-onset risk factor (13). To determine 
a risk factor for health care–associated community-onset 
infection, we obtained history of hospitalization, surgery, 
residence in a long-term care facility, or prior MRSA-
positive culture in the past 12 months before the date and 
time of each index positive MRSA culture. Site of infection 
(bone or joint, skin or soft tissue, endovascular, respiratory, 
intraabdominal/pelvic, central nervous system, urinary 
tract, S. aureus–nonspeciﬁ  c site, bacteremia without focus, 
and other or site not speciﬁ  ed) was determined for each S. 
aureus infection on the basis of matching ICD-9-CM code. 
When cultures matched with multiple ICD-9-CM codes, 
we chose the highest ranking site of infection on the basis 
of the likelihood that a culture represented true S. aureus 
infection (16).
Statistical Analysis
Information about annual number of unique veterans, 
admissions, and total inpatient days for hospitalization, 
long-term care, and residential rehabilitation programs 
were obtained from the VAMHCS Medical Administrative 
Service  ﬁ  scal year (FY) databases. Annual and 10-year 
averaged incidence rates per 100,000 veterans were 
estimated overall and for community-onset infections and 
per 100,000 inpatient days for hospital-onset S. aureus 
infections. To account for the ﬁ  rst 48 hours in the deﬁ  nition 
for hospital-onset infection, we adjusted inpatient days 
(number of annual inpatient days minus 2× the number 
of annual admissions) (13). Because the average inpatient 
length of stay in the VAMHCS is >48 hours, this adjustment 
provides a consistent and reasonably accurate estimate of 
inpatient days past 48 hours.
Trends in all S. aureus infections were initially 
assessed by plotting natural and cubic spline smoothers to 
the observed data plotted as a function of time. The formal 
analysis of trends of all S. aureus infections was based on 
generalized linear models, assuming a Poisson distribution 
with a log link function, including FY as a predictor 
variable and log total number of unique veterans or log-
adjusted inpatient days as an offset variable (17). Model 
ﬁ  t was assessed by evaluating the deviance and Akaike 
information criterion, and regression coefﬁ  cients for trend 
were assessed by the partial Wald test (18,19). Additional 
models were ﬁ  t for each stratum of interest, i.e., invasive, 
noninvasive, onset, and methicillin susceptibility. Analyses 
were performed by using SAS version 9.1 (SAS Institute 
Inc., Cary, NC, USA) and R version 2.7.0 (2008) software 
(www.r-project.org).
Results
For FY 1999–FY 2008, a mean (± SD) of 48,940 (± 
3,926) unique veterans accessed care in the VAMHCS each 
year. The mean annual numbers of acute care and nursing 
home or intermediate care admissions was 5,854 (± 199) 
and 919 (± 161) corresponding to 23,183 (± 1,743) and 
98,902 (± 10,893) inpatient days, respectively.
Overall Incidence of S. aureus Infection
We identi ﬁ  ed 3,674 S. aureus infections, of which 2,816 
(77%) were noninvasive and 2,256 (61%) were MRSA. The 
overall proportion of community-onset and hospital-onset 
infections was 2,517 (69%) and 1,157 (31%), respectively. 
The 10-year averaged incidence per 100,000 veterans was 
749 cases (± 132 SD, range 549–954) overall, 178 (± 41 
SD, range 114–259) invasive, and 571 (± 152 SD, range 
364–801) for noninvasive S. aureus infections. The annual 
incidence per 100,000 veterans of all S. aureus infections 
increased signiﬁ   cantly starting in 2003 (p<0.001). This 
increase was driven by signiﬁ   cant (p<0.001) increases 
in noninvasive, MRSA, and community-onset infections 
(Figure 1).
Invasive S. aureus Infections
We identiﬁ  ed 858 invasive S.    aureus infections, of 
which 75% were based on positive blood cultures, among 
800 unique veterans during FY 1999–FY 2008. The 
proportions of community- and hospital-onset invasive S. 
aureus infections were 56% and 44%, respectively; 52% 
were caused by MRSA (Table 1). Among all 449 invasive 
MRSA infections, 243 (54%) were epidemiologically 
classiﬁ   ed as health care–associated hospital-onset, 152 
(34%) as health care–associated community-onset, and 54 
(12%) as community-associated MRSA.
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The annual incidence of all invasive S. aureus 
infections decreased gradually from FY 1999 through 
FY 2008 (Figure 1, panel A). In FY 1999, the estimated 
incidence of invasive S. aureus infection was 259 
infections per 100,000 veterans; however, by FY 2008, 
incidence was 114 per 100,000 veterans (p<0.001). This 
decrease appears to be associated with overall decreases 
in the incidence of invasive MRSA (135–68/100,000; p = 
0.02) and methicillin-susceptible S. aureus (MSSA) (123–
47/100,000; p = 0.009).
The incidence of invasive hospital-onset S. aureus 
infections decreased from 150 to 85 cases per 100,000 
adjusted acute-care inpatient days (Table 2). Invasive 
hospital-onset MSSA and MRSA infections signiﬁ  cantly 
decreased during the 10-year period (p = 0.01 and p<0.001, 
respectively). The incidence of invasive community-onset 
S. aureus infections decreased 1.9-fold from 119 to 64 per 
100,000 veterans and was driven by decreases in incidence 
of invasive community-onset MSSA. Incidence of invasive 
community-onset MRSA remained relatively unchanged 
(46 to 41/100,000 veterans).
Noninvasive S. aureus Infections
We identiﬁ  ed 2,816 noninvasi    ve S. aureus infections 
among 2,511 unique patients during FY 1999–FY 
2008. Overall, 28% and 72% of S. aureus infections 
were noninvasive hospital onset and community onset, 
respectively; 1,807 (64%) were caused by MRSA and 
1,006 (36%) by MSSA (Table 1). Of MRSA infections, 539 
(30%), 572 (32%), and 696 (39%) were epidemiologically 
classiﬁ   ed as health care–associated community-onset, 
health care–associated community-onset, and community-
associated MRSA infections, respectively.
From FY 1999 through FY 2008, the overall incidence 
of noninvasive S. aureus infections increased signiﬁ  cantly 
(p<0.001) (Figure 1, panel A). Incidence in FY 1999 was 576 
cases per 100,000 veterans and rapidly increased beginning 
in FY 2003, peaking at 801 cases per 100,000 veterans by 
FY 2005. These increases were driven primarily by increases 
in noninvasive MRSA infections, with the most pronounced 
increases occurring during FY 2003 and FY 2004 (Table 2). 
The overall incidence of health care–associated hospital-
onset MRSA infections decreased nonsigniﬁ   cantly (p = 
0.47); however, health care–associated community-onset 
and community-associated MRSA signiﬁ  cantly  increased 
(p<0.001), particularly after FY 2003.
The incidence of noninvasive hospital-onset infections 
did not follow any apparent increasing or decreasing trend 
(p = 0.08; Table 2). However, driven by noninvasive MRSA 
infections, the overall incidence of noninvasive community-
onset S. aureus infections increased signiﬁ  cantly (p<0.001). 
Incidence after FY 2003 rapidly increased from 218 to 546, 
peaking at 644 cases per 100,000 veterans in FY 2005. 
After FY 2000, incidence of noninvasive community-onset 
MRSA infections increased 4-fold from 100 to 397 cases 
per 100,000 veterans. Incidence of noninvasive community-
onset MSSA infections did not change (p = 0.83; Table 2).
A total of 1,703 (61%) noninvasive infections were 
classiﬁ   ed as SSTIs of which 1,112 (65%) were caused 
by MRSA. Changes in incidence of overall noninvasive 
MRSA infections were driven by increases in MRSA SSTIs 
(Figure 2). Incidence per 100,000 veterans signiﬁ  cantly 
increased from 90 cases in FY 1999 to 345 in FY 2008 
(p<0.0001); the largest increase began in FY 2003 and 
incidence peaked at 440 cases in FY 2005.
Discussion
We have described the incidence of all S. aureus 
infections during a 10-year period in a large US-based 
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  Figure 1. Incidence per 100,000 veterans of Staphylococcus 
aureus infections by invasive and noninvasive (A), methicillin 
susceptibility (B), and onset (C), Veterans Affairs Maryland Health 
Care System, ﬁ  scal years 1999–2008. Solid line represents all S. 
aureus infections. MRSA, methicillin-resistant S. aureus; MSSA, 
methicillin-susceptible  S. aureus; CO, community onset; HO, 
hospital onset.  S. aureus Infections in US Veterans
population (49,000 persons) using person-level data 
including clinical culture and administrative data to identify 
and classify infections. Our results suggest signiﬁ  cant 
increases in overall S. aureus infections from FY 1999 
through FY 2008; the largest increases were associated 
with community-onset MRSA infections of skin and soft 
tissue and an overall decrease in incidence of invasive S. 
aureus infections.
During the study period, we implemented many new 
hospital infection–control practices—including the use of 
alcohol-based hand gels for hand hygiene (2003), central 
line bundles (2006), MRSA surveillance cultures (intensive 
care units in 2003, expanded to acute care in 2007), and 
chlorhexidine bathing of all surgical patients (2009)—
which may have contributed to the decreased incidence of 
invasive infections. Previous studies suggest that improved 
infection control practices have contributed to fewer 
catheter-related and central line–associated bloodstream 
infections (20,21). However, attributing the decrease to 
a single practice is difﬁ  cult, if not impossible, and few 
published studies exist with which we can compare our 
invasive S. aureus results.
Laupland et al. estimated an annual incidence of 
invasive S. aureus of 28 cases per 100,000 population, but 
their results may not be comparable because they were 
based primarily on MSSA infections (12). Klevens et al. 
estimated an incidence of invasive MRSA infection of 32 
cases per 100,000 population, 75% were bacteremias, and 
27% were hospital-acquired on the basis of 2005 data from 
9 US cities (13). Their study reported a noticeably higher 
incidence of invasive MRSA in Baltimore, Maryland, 
USA, of 117 per 100,000 compared with estimates of 20–
50 per 100,000 population at other sites. Our estimated rate 
of invasive MRSA infection (160 cases/100,000 veterans) 
is commensurate during the same year (2005), and our 
calculated proportion of invasive hospital-onset MRSA 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011  445
Table 1. Characteristics of Staphylococcus aureus infections, Veterans Affairs Maryland Health Care System, fiscal years 1999–2008* 
Characteristic
Invasive S. aureus infections  Noninvasive S. aureus infections 
Total,
n = 858 
Onset Susceptibility 
Total,
n = 2,816 
Onset Susceptibility† 
H,
n = 381 
C,
n = 477 
MRSA,
n = 449 
MSSA,
n = 409 
H,
n = 778 
C,
n = 2,038 
MRSA,
n = 1,807 
MSSA,
n = 1,006 
No. patients  800 359 441 415 385 2,511  708 1,803  1,600  908
Age, y‡ 
  Mean (SD)  64 (14)  67 (13)  61 (13)  65 (13)  62 (14)  62 (14)  68 (13)  60 (14)  62 (14)  62 (14) 
Median 64 70 60 65 61 61 71 58 61 60
Range  28–98  28–98  30–94  28–97  29–98  19–94 19–93 22–94  23–94  19–93 
Male sex,  
no. (%) 
782 (98)  370 (97)  469 (98)  399 (98) 440 (98) 2,436 (97) 691 (98) 1,745 (97)  1,552 (97) 881 (97) 
Race, no. (%) 
  Black  393 (49)  154 (43)  239 (54)  190 (48) 203 (53) 1,212 (48) 289 (41) 923 (51)  781 (49)  429 (47) 
  White  387 (48)  200 (56)  187 (42)  217 (52) 170 (44) 1,186 (47) 412 (58) 774 (43)  745 (47)  440 (49) 
  Other§  20 (3)  5 (1)  15 (3)  8 (2)  12 (3)  113 (5)  7 (1)  106 (6)  74 (5)  39 (4) 
*MRSA, methicillin-resistant S. aureus. MSSA, methicillin-susceptible S. aureus; H, hospital; C, community. 
†Methicillin-susceptibility unknown for 3 patients with noninvasive S. aureus infections. 
‡Age unknown for 8 patients with noninvasive S. aureus infections. 
§Includes missing data. Other/unknown race not included in test. 
Table 2. Incidence and type of Staphylococcus aureus infections, Veterans Affairs Maryland Health Care System, fiscal years 1999–
2008*
Fiscal year 
Invasive infection  Noninvasive infection 
Hospital onset†  Community onset‡  Hospital onset†  Community onset‡ 
MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA
1999 46.3 104.1  72.6 46.0 88.7 250.7  246.7  113.7 
2000 58.4 75.1 72.4 44.4 116.8  183.5  142.5  100.5 
2001 50.6 109.6  66.3 27.8 139.1  273.9  117.6  119.7 
2002 58.1 116.1  57.5 31.7 111.7  254.6  150.8  107.1 
2003 53.2 87.1 59.0 43.3 135.5  222.6  104.2  114.0 
2004 24.3 72.8 59.2 51.3 140.8  301.0  165.8  286.3 
2005 33.5 54.4 47.1 41.2 62.8 272.1  176.6  467.0 
2006 59.3 59.3 57.5 46.0 91.2 150.4  164.8  360.2 
2007 29.3 37.7 46.3 48.3 87.9 196.8  162.2  451.7 
2008 40.3 44.3 23.3 40.7 64.4 221.5  149.2  397.2 
Average 45.3 76.0 56.1 42.1 103.9  232.7  158.0  251.8 
*MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus.
†Incidence per 100,000 adjusted acute-care inpatient days. 
‡Incidence per 100,000 veterans. RESEARCH
in 2005 (20%) also was similar. Klevens et al. reported 
estimates per 100,000 persons; therefore a direct comparison 
of rates of invasive hospital-onset MRSA infection is not 
feasible. However, our rates are potentially higher given 
the inpatient days adjustment accounting for the ﬁ  rst 48 
hours in the deﬁ  nition for hospital-onset infection. Another 
study by Laupland et al. reported an annual incidence of 
S. aureus bloodstream infections during 2000–2006 of 20 
per 100,000 population (14). However, few MRSA cases 
were identiﬁ  ed in this study, thereby making it difﬁ  cult to 
compare with our results for which MRSA caused almost 
half of infections.
For several reasons, our incidence rates of invasive 
infections are higher than those previously reported. Black 
race has previously been reported as a marker for increased 
risk for invasive MRSA infections (13,22). Therefore, we 
would expect a higher incidence of all S. aureus infections, 
given that in our study 49% of patients were black. 
Additionally, given that our study was performed on data 
from a primarily urban population located in or around 
Baltimore, we could attribute the higher incidence of 
infections to suspected risk factors that are more prevalent 
in this location, including intravenous drug use.
Our study identiﬁ  ed increases in noninvasive S. aureus 
infections, particularly around 2003, which most likely 
are associated with the emergence of the USA300 MRSA 
clone that has led to increases in community-associated 
MRSA, speciﬁ  cally in SSTIs (1,22). Also, despite dramatic 
increases in noninvasive community-onset MRSA 
infections, we did not observe a proportionate increase in 
invasive community-onset MRSA as might be expected if 
USA300 MRSA had the same propensity as non-USA300 
MRSA to invade the bloodstream. No population-based 
studies have been published with which to compare 
overall noninvasive S. aureus infections, and few exist for 
comparison of noninvasive MRSA infections. For instance, 
Liu et al. recently reported annual (2004–2005) incidence 
rates of community-acquired and hospital-acquired MRSA 
among residents in San Francisco, California, USA, 
community-associated of 316 and 31 cases per 100,000 
population, respectively, for which most cultures were 
from skin and soft tissue (8). The results of our study for 
community-onset MRSA are slightly lower but similar. 
Crum et al. reported a dramatic increase during 2002–2004 
in community-associated MRSA infections, of which most 
were classiﬁ  ed as SSTIs, and an incidence rate of 155 cases 
per 100,000 persons from 2004 data (7). The FY 2004 
incidence of noninvasive community-associated MRSA 
in our study was 188 cases per 100,000 veterans, which is 
similar to that reported by Crum et al.
Our study adds new information to the existing 
literature and has several strengths. A major strength is its 
calculation of annual incidence of all S. aureus infections 
for a 10-year period by using actual numbers of patients 
at risk, admissions, and inpatient days. Our estimates 
of incidence are more accurate than those in previous 
studies, which were based on census-level data (11–
13,23). Noninvasive infections were identiﬁ  ed by using 
an automated approach that required both positive clinical 
culture and conﬁ   rmed ICD-9-CM code for infection. 
This deﬁ   nition is more rigorous, thereby producing 
higher positive predictive values than clinical cultures 
alone, particularly for infections of bone and skin or soft 
tissue (16). In addition, this automated approach enabled 
us to identify and classify types of S. aureus infection, 
which is useful for understanding the overall population 
distribution of infection. Access to comprehensive, patient-
level information, including prior hospitalizations, prior 
MRSA infections, and surgeries, allowed us determine the 
epidemiologic class for all MRSA infections. This study 
was performed in a population receiving standardized 
health care; therefore, ﬁ   ndings should be free of bias 
associated with access to care or duration and type of 
treatment received.
Our study also has several limitations. First, the 
VAMHCS population of adult, mostly male patients living 
in the mid-Atlantic region does not fully represent the 
overall US population. We are unable to extrapolate these 
ﬁ  ndings to children, a population for which an increase of 
community-onset MRSA SSTIs has been reported (24). 
Previous reports suggest that men are at higher risk than 
women for S. aureus infections; therefore, our estimates 
may overestimate true rates for women (8,12,13). Second, 
although we did not perform molecular typing on the S. 
aureus–positive isolates, we expect that a signiﬁ  cant 
proportion (>80%) of noninvasive MRSA infections were 
caused by the USA300 MRSA strain (1). Given that USA300 
MRSA reportedly varies across the United States, our 
ﬁ  ndings may not be generalizable to populations in which 
MRSA strains differ. Third, we may have underestimated 
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Figure 2. Incidence per 100,000 veterans of skin and soft tissue 
infections (SSTIs) caused by methicillin-resistant Staphylococcus 
aureus (MRSA) and methicillin-susceptible S. aureus (MSSA), 
Veterans Affairs Maryland Health Care System, ﬁ  scal years 1999–
2008.S. aureus Infections in US Veterans
incidence because our deﬁ  nition  of  S. aureus infection 
required a positive clinical or blood culture. However, given 
the standardized access to care in the VAMHCS, we expect 
that cultures were uniformly collected in patients who had 
clinical signs or symptoms of infection. Fourth, the clinical 
culturing rate may have increased during our study period, 
which would contribute to overestimates in the incidence 
of S. aureus infection, particularly noninvasive infections. 
Johnston et al. observed an increase in the absolute number 
of SSTI cultures obtained in the VAMHCS Emergency 
Care Service (1). However, they determined that the 
proportion of MRSA infections increased, even though the 
proportion of MSSA remained the same, which suggests 
a true increase in MRSA. We observed similar patterns: 
whereas MRSA infections increased, MSSA infections 
remained relatively stable, and the annual number of S. 
aureus cultures did not signiﬁ  cantly change.
In conclusion, this large, population-based study 
demonstrated an increase in the overall incidence of S. 
aureus infections during FY 1999–FY 2008, which was 
driven by a rapid increase in noninvasive, community-
onset, MRSA skin and soft tissue infections. This 
increase was most striking during and after 2003, which 
is coincident with the time during which the USA300 
clone became a major contributor to noninvasive S. aureus 
infections. Despite this increase, incidence of invasive 
community-onset MRSA infections did not signiﬁ  cantly 
increase, and the overall MSSA infections and noninvasive 
MSSA infections remained generally stable. These results 
suggest a shift in the distribution of S. aureus infections 
to more noninvasive community-onset MRSA infections. 
This information is useful for interpreting changes in 
the epidemiology of S. aureus infections, which may 
help guide additional prevention strategies focused on 
reducing community-onset S. aureus infections. To further 
understand these trends, additional studies are warranted to 
identify risk factors for S. aureus infection and to describe 
the epidemiology of S. aureus infections across the entire 
population.
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